2012-02-14 18:26:14 -

GHENT, Belgium, 14 February 2012 - Ablynx [Euronext Brussels: ABLX], today
announced that it has appointed Dr Andreas Menrad as its Chief Scientific
Officer.

Dr Menrad has over 20 years experience in the pharmaceutical and biotech
industry, with significant expertise in drug discovery and the successful
progression of lead candidates into pre-clinical development. He will head up
the research activities, be responsible for the ongoing development of the
Nanobody(®) platform, and identify and prioritise new therapeutic programmes
that Ablynx will take forward either on its own or with partners to help
continue building the rapidly growing portfolio of Nanobody development
candidates.

Prior to joining Ablynx, Dr Menrad was at Genzyme for five years, where since
2011 he held the position of General Manager and Vice President of Antibody
Therapeutics. Previously he has also   held senior research positions with
Schering AG.

Dr Menrad received his Ph.D. in immunology from the University Stuttgart in
1989. He then took a post-doctoral position at The Wistar Institute Cancer
Center in Pennsylvania, USA.

Dr Edwin Moses, CEO and Chairman, said: "We are delighted that Andreas is
joining us to head up the research activities at Ablynx. He brings with him a
wealth of knowledge and experience in the drug discovery area with a strong
expertise in biologics, which will further strengthen and complement our
existing management team, and will help us to continue to develop and exploit
our Nanobody platform over a wide range of therapeutic areas."

Commenting on his appointment, Dr Menrad said: "I am excited to join Ablynx at
this very important time and I am looking forward to contributing to the already
very strong Nanobody platform and portfolio of products. I am impressed by the
broad applicability of the Nanobody technology to different target classes
including GPCRs and ion channels which have proven challenging for conventional
antibodies. I am also keen to build on the fact that Nanobodies can be
administered through non-injectable routes such as inhalation, as shown by the
anti-RSV Nanobody currently in Phase I trials."


For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com






Complete version of the press release: 
 hugin.info/137912/R/1585652/496507.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Ablynx via Thomson Reuters ONE

[HUG#1585652]